meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced UC (mUC) - maintenance (M)
mUC - M - all population
1
mUC - M - PDL1 positive
1
immune chekpoint inhibitors
anti-PD-(L)1
avelumab based treatment
avelumab alone
versus all
vs non active control
vs BSC
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DCR
deaths (OS)
deaths (OS) (extension)
objective responses (ORR)
PFS (extension)
progression or deaths (PFS)
DCR
mUC - M - PDL1 positive
metastatic/advanced UC (mUC) - maintenance (M)
mUC - M - PDL1 positive
versus BSC
avelumab alone vs. BSC
1
certainty unassessable
+103%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open